Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Melcher

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
Nature Medicine|December 11, 2007
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapyJian Qiao, Timothy Kottke, Candice Willmon, et al.
Neuro-Oncology|September 28, 2015
Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profilingJulia V Cockle, Karishma Rajani, Shane Zaidi, et al.
Cancer Research|March 13, 2024
FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNAAnn-Marie Baker, Gayathri Nageswaran, Pablo Nenclares, et al.
Nature Medicine|June 21, 2011
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsTimothy Kottke, Fiona Errington, Jose Pulido, et al.
Molecular Therapy Oncolytics|April 20, 2023
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cellsMatthew Holmes, Gina B Scott, Samuel Heaton, et al.
Molecular Therapy Oncolytics|July 11, 2018
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 VirusNicola E Annels, Mehreen Arif, Guy R Simpson, et al.
Science Advances|June 5, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activityOlivia Liseth, Elizabeth Appleton, Benjamin Kendall, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2014
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsShane Zaidi, Miran Blanchard, Kevin Shim, et al.
Nature Medicine|November 19, 2013
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrenceTimothy Kottke, Nicolas Boisgerault, Rosa Maria Diaz, et al.
Translational Oncology|December 14, 2022
Corrigendum to "Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers": Translational Oncology 2022 Nov; 25:101511Aruna Korlimarla, P S Hari, Jyoti Prabhu, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Nature Medicine|December 11, 2007
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapyJian Qiao, Timothy Kottke, Candice Willmon, et al.
Neuro-Oncology|September 28, 2015
Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profilingJulia V Cockle, Karishma Rajani, Shane Zaidi, et al.
Cancer Research|March 13, 2024
FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNAAnn-Marie Baker, Gayathri Nageswaran, Pablo Nenclares, et al.
Nature Medicine|June 21, 2011
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsTimothy Kottke, Fiona Errington, Jose Pulido, et al.
Molecular Therapy Oncolytics|April 20, 2023
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cellsMatthew Holmes, Gina B Scott, Samuel Heaton, et al.
Molecular Therapy Oncolytics|July 11, 2018
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 VirusNicola E Annels, Mehreen Arif, Guy R Simpson, et al.
Science Advances|June 5, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activityOlivia Liseth, Elizabeth Appleton, Benjamin Kendall, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2014
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsShane Zaidi, Miran Blanchard, Kevin Shim, et al.
Nature Medicine|November 19, 2013
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrenceTimothy Kottke, Nicolas Boisgerault, Rosa Maria Diaz, et al.
Translational Oncology|December 14, 2022
Corrigendum to "Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers": Translational Oncology 2022 Nov; 25:101511Aruna Korlimarla, P S Hari, Jyoti Prabhu, et al.
Pageof 14